<?xml version="1.0" encoding="UTF-8"?>
<p id="Par29">Here, we collected drug–target interaction information from the DrugBank database (v4.3)
 <sup>
  <xref ref-type="bibr" rid="CR86">86</xref>
 </sup>, Therapeutic Target Database (TTD)
 <sup>
  <xref ref-type="bibr" rid="CR87">87</xref>
 </sup>, PharmGKB database, ChEMBL (v20)
 <sup>
  <xref ref-type="bibr" rid="CR88">88</xref>
 </sup>, BindingDB
 <sup>
  <xref ref-type="bibr" rid="CR89">89</xref>
 </sup>, and IUPHAR/BPS Guide to PHARMACOLOGY
 <sup>
  <xref ref-type="bibr" rid="CR90">90</xref>
 </sup>. The chemical structure of each drug with SMILES format was extracted from DrugBank
 <sup>
  <xref ref-type="bibr" rid="CR86">86</xref>
 </sup>. Here, drug–target interactions meeting the following three criteria were used: (i) binding affinities, including 
 <italic>K</italic>
 <sub>i</sub>, 
 <italic>K</italic>
 <sub>d</sub>, IC
 <sub>50</sub>, or EC
 <sub>50</sub> each ≤10 μM; (ii) the target was marked as “reviewed” in the UniProt database
 <sup>
  <xref ref-type="bibr" rid="CR91">91</xref>
 </sup>; and (iii) the human target was represented by a unique UniProt accession number. The details for building the experimentally validated drug–target network are provided in our recent studies
 <sup>
  <xref ref-type="bibr" rid="CR13">13</xref>,
  <xref ref-type="bibr" rid="CR23">23</xref>,
  <xref ref-type="bibr" rid="CR28">28</xref>
 </sup>.
</p>
